Generic Name and Formulations:
Vardenafil (as HCl) 2.5mg, 5mg, 10mg, 20mg; tabs.
Bayer and GlaxoSmithKline
Indications for LEVITRA:
Take once daily as needed, about 1hr before sexual activity. Initially 10mg; range: 5–20mg. Elderly (≥65yrs): initially 5mg. Moderate hepatic impairment: initially 5mg; max 10mg. Concomitant ketoconazole 200mg or itraconazole 200mg daily, or erythromycin: max 5mg. Concomitant indinavir, saquinavir, atazanavir, ketoconazole 400mg or itraconazole 400mg daily, clarithromycin: max 2.5mg. Concomitant ritonavir: max 2.5mg/72hrs. Concomitant α-blocker: initially 5mg/day.
Concomitant nitrates, or nitric oxide donors. Concomitant guanylate cyclase (GC) stimulators (eg, riociguat).
Not for use in women. Confirm diagnosis before therapy. Congenital QT prolongation: avoid use. Cardiovascular disease (eg, MI, stroke or life-threatening arrhythmia within 6 months; systolic BP <90mmHg or BP >170/110mmHg; unstable angina, LV outflow obstruction, severe heart failure), severe hepatic impairment, on renal dialysis, hereditary degenerative retinal disorders and retinitis pigmentosa: not recommended. Anatomical penile deformation. Predisposition to priapism. History of non-arteritic anterior ischemic optic neuropathy (NAION) or those with "crowded" optic disc. Advise patients to discontinue if sudden vision or hearing loss occurs. Patients for whom sexual activity is inadvisable or contraindicated. Bleeding disorders. Active peptic ulcer. Pregnancy (Cat.B).
Phosphodiesterase type 5 inhibitor (cGMP-specific).
See Contraindications. Hypotension with nitrates, GC stimulators. Avoid Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmics, others that cause QT prolongation. Additive hypotensive effects with concomitant α-blockers, other antihypertensives; caution. Potentiated by moderate or potent CYP3A4 inhibitors (eg, erythromycin, clarithromycin, ketoconazole, itraconazole, indinavir, saquinavir, atazanavir, ritonavir, grapefruit juice). Concomitant other erectile dysfunction treatments: not recommended.
Headache, flushing, nasal congestion, dyspepsia, sinusitis, flu syndrome, dizziness, increased creatine kinase, nausea, back pain, sudden vision or hearing loss, cardiovascular effects; rare: priapism, prolonged erection.
Neurology Advisor Articles
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Natalizumab Improves Cognitive Function in Multiple Sclerosis
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- Smoking Promotes Disease Progression in Multiple Sclerosis
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- ZTlido Patch for Post-Shingles Pain Launching Soon
- Managing Complications of Intrathecal Baclofen Therapy
- Deep Brain Stimulation Reduces Tremor Symptoms in Parkinson Disease
- FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid
- Prevalence of Autoimmune Encephalitis in Herpes Simplex Encephalitis Explored